Sodium hyaluronate intra-articular solution for viscosupplementation, supplied in three presentations: Reviscon, Reviscon Plus and Reviscon Mono. CE marked, Play Sure Doping Free certified.
Not to scale. Product shown enlarged for detail.
Reviscon 1.0%, Reviscon Plus 1.6% and Reviscon Mono 2.0% are indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, for example acetaminophen (paracetamol). Administered by intra-articular injection by a qualified physician.
Reviscon: 3 to 5 injections, one week apart. Reviscon Plus: 1 to 3 injections. Reviscon Mono: a single injection, every six months.
Intra-articular injection by a qualified physician. Do not inject intravenously. Strict aseptic technique required.
Reviscon is Play Sure Doping Free certified and contains no prohibited substances. Safe for use in competitive athletes subject to WADA testing. Confirm current WADA list at time of use.
Reviscon is supplied in three presentations that differ in injection regimen. Formulation, indication and doping-free certification are common to all three. Select by treatment protocol and patient profile.

The reference presentation. A graduated weekly course for osteoarthritis of the knee.

The same indication with fewer injections. For protocols and patients where visit count matters.

A single injection, every six months. For patients where a weekly course is not practical.
Formulation data, regulatory classification, injection parameters, and handling requirements for Reviscon sodium hyaluronate. Values shown are for the standard Reviscon presentation.
In osteoarthritic joints, endogenous HA concentration falls and the average molecular weight decreases, reducing synovial fluid viscosity. The result is impaired joint lubrication, increased cartilage stress under load, and progressive pain. Reviscon restores the viscoelastic properties of the synovial fluid through direct supplementation with exogenous sodium hyaluronate.
For healthcare professionals. Always refer to the current instructions for use (IFU) before clinical use.
Prospective study of the Reviscon sodium hyaluronate portfolio (Reviscon, Plus and Mono) in knee osteoarthritis. Overall WOMAC scores for pain, stiffness and physical function fell by an average of 42% across all patient groups over six months.
In the same portfolio study, overall VAS scores for rest pain, movement pain and quality of life fell by an average of 35% across all patient groups over six months. Reviscon is clinically proven and effective up to six months.
Intra-articular viscosupplementation with Reviscon is a safe, well-tolerated procedure for patients with osteoarthritis who have not responded sufficiently to prior pharmacologic treatment. Report suspected side effects to the VSY Biotechnology Quality team at complaint@vsybiotechnology.com.